The aim of this study was to determine the prevalence of invasive aspergillosis (IA) in patients with liver cirrhosis and the performance of serum galactomannan (GM) screening. Patients with decompensated liver cirrhosis and patients with compensated liver cirrhosis presenting with fever and/or respiratory symptoms were prospectively enrolled. All patients were screened by serum GM twice weekly irrespective of clinical signs and symptoms. Positive serum GM triggered work-up consisting of chest computed tomography and in case of pathological findings bronchoscopy. 150 patients were included in the study. Two (1.3%) had probable, one (0.7%) had possible, and 147 (98%) had no evidence of IA. Both patients with probable IA had compensated liver cirrhosis. Sensitivity for serum GM screening for probable versus no IA was 0.5 (95% CI, 0.09-0.91), specificity 0.97 (95% CI: 0.92-0.99), negative predictive value 0.99 (95% CI, 0.96-0.99) and positive predictive value (PPV) 0.17 (95% CI, 0.01-0.64). PPV was 0.5 (95% CI, 0.03-0.98) in patients with clinical suspicion of IA. In conclusion, prevalence of IA in patients with liver cirrhosis seems to be low. Targeted GM testing in case of clinical suspicion of IA may be associated with markedly higher PPVs when compared to universal GM screening in patients with liver cirrhosis.
Introduction
Invasive aspergillosis (IA) is a disease primarily affecting immunocompromised patients 1 . Several factors, for example, prolonged neutropenia as well as glucocorticoid use in case of graft-versus-host disease predispose patients for IA. Recently, IA has also increasingly been reported in critically ill patients without hematological malignancies and solid organ transplant recipients. [2] [3] [4] In some of them liver cirrhosis was the only relevant underlying disease. 2, 5, 6 Thereafter, several cases of IA in patients with liver cirrhosis were published, the majority in patients suffering from end-stage liver cirrhosis. 3, [6] [7] [8] [9] [10] Potential reasons for IA development in cirrhotic patients, even in the absence of systemic glucocorticoid therapy, are diverse. Both systemic inflammation due to cirrhosis as well as immunodeficiency occur within cirrhosis and are summarized as cirrhosis-associated immune dysfunction syndrome. 11 Alterations of the innate as well as adaptive immune functions result in an increased susceptibility to infections. Resident macrophages in the lungs, the primary side of Aspergillus spp. infections in cirrhosis patients, 7 are the first line of defense and are able to phagocyte more than 10 8 conidia every day. 12 In cirrhotic patients however, impaired function of the Fcγ -receptor of neutrophils is causing higher susceptibility for infections. 13 Neutrophil mobilization, phagocytic activity, monocyte spreading, chemotaxis, bacterial phagocytosis, and killing are also decreased in cirrhosis contributing to high vulnerability for infections. 14, 15 Also low platelet count, a condition often observed in patients with cirrhosis, may be associated with a higher vulnerability to Aspergillus spp. infections, as platelets were shown to have a growth inhibiting effect on Aspergillus spp. in vitro. 16 Patients with liver cirrhosis therefore have several risk factors that may contribute to a high vulnerability to Aspergillus spp. infections. As no prospective data regarding the prevalence of IA in these patients have been published to date, we investigated the prevalence of IA in patients with liver cirrhosis.
Methods
The aim of this prospective, observational cohort study was to assess the prevalence and outcome of IA in patients with liver cirrhosis and to determine the performance of serum GM screening in this cohort.
The study was conducted between June 2013 and November 2015 at the University Hospital of Graz, Austria, a tertiary care hospital with a capacity of approximately 1,500 beds.
Patients
Patients were recruited by daily screening (from Monday to Friday and retrospectively on Monday for the preceding weekend) of patient protocols at the emergency department, the gastroenterology department and the medical intensive care unit (ICU [all Department of Internal Medicine]) and by twice weekly chart reviewing at the Division of Transplant Surgery, Department of Surgery. All adult (>18 years) patients with underlying liver cirrhosis admitted to the hospital were considered eligible for study inclusion and checked for inclusion criteria. Patients were only included once in this study. Thus, patients who were readmitted to our hospital were not included in this study for a second time. Inclusion criteria were (1) patients with decompensated liver cirrhosis regardless of reason for admission or patients with compensated liver cirrhosis and respiratory symptoms (cough, dyspnea, pleuritic pain, hemoptysis) and/or fever, (2) informed consent. Patients who were unable to give informed consent at the time of admission (e.g., due to hepatic encephalopathy) were informed and asked for their consent as soon as their condition improved and could withdraw from the study at this point according to the approval of our ethics committee. Patients were classified as having compensated or decompensated liver cirrhosis using a previously published classification system. 17 
Sampling and diagnostic management
A serum sample for galactomannan-antigen-testing (GM) was collected from patients within 24 h after study inclusion and twice weekly thereafter until patients were discharged. In case patients were hospitalized for 4 weeks or longer and had no signs or symptoms of IA within the first 4 weeks, serum GM screening was reduced to once weekly from week 5 onward. In case of a positive serum GM result, high resolution computed tomography (HR-CT) of the chest was performed to rule out or confirm pulmonary IA. CT scans were also performed in patients with clinical symptoms suggestive of IA at the discretion of the treating physician. If radiographic signs suggestive of pulmonary IA were present (i.e., small nodules [<1 cm], consolidations, large nodules, peribronchial infiltrates, ground-glass infiltrates 18, 19 ), bronchoscopy with bronchoalveolar lavage fluid (BALF) sampling, GM determination in BALF and culture were performed. In case of consistent positive serum GM and negative chest HR-CT scan, CT scans of the paranasal sinuses, the cranium, and abdomen were performed to check for alternative sites of infection. GM concentrations were determined by using the Platelia Aspergillus EIA (Bio-Rad, Vienna, Austria) test kits according to the manufacturer's instructions at the Institute of Hygiene, Microbiology, and Environmental Medicine, Medical University of Graz, Austria. GM results with an optical density index (ODI) ≥0.5 were considered positive in case of serum samples and ≥1 in case of testing BALF samples. Serum GM performance was calculated for all tested patients and for two subgroups: (1) patients presenting with respiratory symptoms; (2) patients with clinical 
Results
In sum, 154 patients were initially included in our study; 150 were included in the final analysis. Four patients were excluded from the final analysis for the following reasons: diagnosis of liver cirrhosis was mentioned at the emergency department but retrospectively rejected (n = 2), patient death before the first serum GM screening sample was drawn (n = 1), patient who was included within an episode of hepatic encephalopathy and not able to give informed consent at the time of inclusion refused to give informed consent after clinical improvement (n = 1). Demographic data and patient characteristics are displayed in Table 2 .
Probable and possible IA cases He was readmitted for pre-liver transplant evaluation one week prior to study inclusion. At readmission CRP levels were elevated (71 mg/l; upper limit of norm = 5 mg/l) without clinical signs of infection and levofloxacin was added to fluconazole. Positive serum GM (0.6), performed after study inclusion, triggered chest HR-CT, revealing multiple, bi-lobular areas of consolidation. Fluconazole was stopped and voriconazole therapy was initiated based on CT and GM results, and bronchoscopy was routinely scheduled and performed 9 days after initiation of voriconazole therapy. BALF GM determination revealed a negative result (0.38 ODI). All consecutively performed serum GM levels were negative. The patient was doing well after discontinuation of voriconazole and received a liver transplant 6 month after study inclusion. Patient 2 had underlying alcoholic liver cirrhosis (Child-Pugh score of 5, model for end-stage liver disease score of 14). The patient presented to our emergency department with hemoptysis since one day. He had an ongoing history of smoking (approximately 30 pack years) but no history of chronic obstructive pulmonary disease (COPD). All serum GM testings remained negative. HR-CT scan of the chest was performed, showing single ground-glass opacity with 1.8 cm in diameter in the left upper lobe. Bronchoscopy yielded tracheobronchitis and BALF GM was 3.44 ODI. No evidence of pulmonary malignancy was obtained. Patient 1 and 2 received oral voriconazole therapy for 6 and 2 weeks, respectively, with a loading dose of 400 mg twice daily on day 1 followed by a maintenance dose of 200 mg twice daily. Therapeutic drug monitoring was performed in both patients. In patient 1 six out of nine (66.7%) samples were in the range of 1-5.5 mg/l, two were below 1 mg/l, and one was higher than 5.5 mg/l. In patient 2 three out of three samples were within the range of 1-5.5 mg/l. Voriconazole therapy was well tolerated in both patients, besides a slight and temporary blurred vision in patient 1. Bilirubin, aspartate transaminase (AST), and alanine transaminase (ALT) levels before, during, and after voriconazole therapy for both patients are displayed in Figure 1 . Both patients improved clinically after voriconazole was initiated and survived.
One patient was diagnosed with possible IA. The patient suffered from IgG4-related sclerosing cholangitis and iridocyclitis. Due to the presence of iridocyclytis the patient was on low dose systemic prednisone therapy (0.11 mg/kg/d) for more than a year. The patient presented to the emergency department because of a prolonged headache. Because of elevated serum CRP level (212 mg/l) a chest X-ray was performed, showing a macronodule in the right upper lung. Lumbar puncture was unsuspicious. HR-chest-CT scan confirmed presence of two macronodules without a halo sign or air crescent sign in the right upper lung. Due to unclear etiology of lung nodules the patient was put on voriconazole with 6 mg/kg on day 1 and 4 mg/kg from day 2 on and piperacillin/tazobactam. BALF GM as wells as serum GM and 1-3-beta-d-glucan yielded negative results. Thus, voriconazole was discontinued after 3 days. CT guided puncture of the nodules showed no evidence for fungal infection but presence of inflammatory IgG4-related pseudotumor. Voriconazole was stopped after 3 days. The patient improved clinically with piperacillin/tazobactam and without antifungal therapy. 
Serum galactomannan performance
During the study 505 serum samples (median 3 per patient; range 1-13) and five BALF samples were obtained and tested for GM. Positive serum GM results were observed in six patients (five without evidence for IA and one with probable IA [patient 1]). Serum GM performance calculation for the overall study cohort, for patients with respiratory symptoms and for patients with clinical suspicion for IA are displayed in Table 3 .
False positive serum GM results were observed in five patients (3.3%) without evidence for IA. None of these patients had received piperacillin/tazobactam. In two patients, only one test resulted positive (1.36 and 0.59 ODI, respectively) while all consecutive tests remained negative, two further patients had two consecutive positive test results (0.56 and 0.54 ODI and 0.53 and 1.21 ODI, respectively) and one patient had 10 consecutive positive serum GM results (range 0.71-4.58 ODI) without a single negative GM test result. In the latter patient, serum BDG, serum Aspergillus specific lateral-flow device test as well as whole blood Aspergillus specific and panfungal real-time polymerase chain reaction turned out negative. CT scans of paranasal sinuses, neurocranium, chest, and abdomen showed no evidence of fungal infection; thus no antifungal therapy was initiated. Despite the lack of antifungal therapy, the patient did not develop an invasive fungal infection and survived.
Mortality
The 90-day mortality rate was 16.7% (25/150) . None of the patients with probable or possible IA died during the study period. One patient died within 24 h of admission and study inclusion. Kaplan-Meier survival curves for patients in various Child-Pugh stages are displayed in Figure 2 .
Discussion
We performed serum GM screening in patients with liver cirrhosis and found a prevalence for probable IA of 1.3%.
Serum GM screening showed a particular low PPV of 17% when screening all patients with decompensated liver cirrhosis or compensated liver cirrhosis plus respiratory signs and symptoms, while the PPV was improved to 50% when testing only those patients with clinical suspicion of IA. To our knowledge, this is the first prospective study investigating the prevalence of IA in patients with liver cirrhosis and evaluating the diagnostic performance of serum GM screening in this cohort.
Liver disease was recognized fairly recently as an important risk factor for IA. 2, 6, 7, 22, 23 A particularly high number of IA cases was published previously by Gustot and colleagues in patients with underlying severe alcoholic hepatitis. 22 They found a prevalence of approximately 16%
in their study cohort. Seventy percent of their study population received immunosuppressive therapy with systemic corticosteroids for alcoholic hepatitis which may account for this high number of cases and the devastatingly low transplant free survival rate of 0% in IA patients. 22 Survival of patients without IA in that study was significantly higher (53%). The markedly lower IA prevalence (1.3%) found in this study may be explained by the fact that only eight patients (5.3%) of our study population received systemic glucocorticoid therapy of whom only three received high dose glucocorticoid therapy (as opposed to 70% in the study by Gustot and colleagues). This may be of particular interest as systemic high-dose glucocorticoid use (≥0.3 mg/kg/d prednisone equivalent for ≥3 weeks) is a well-recognized risk factor for IA and also part of the EORTC/MSG criteria. 20 In addition, glucocorticoids affect virtually every cell line involved in immune system resulting in cellular immunodeficiency. 25 Other immunosuppressive agents were rare in this study making it impossible to conclude whether these agents increase the risk for IA development in cirrhotic patients.
Other diseases besides cirrhosis however, may contribute to the development of IA. One patient with probable IA suffered from type 1 diabetes mellitus. This may be considered an additional risk factor for IA. In our patient, however, A1C serum level was 24 mmol/mol (= 4.2% A1C). Thus, diabetes in this patient was very well controlled, making it unlikely to be associated with an increased risk for IA. Besides liver cirrhosis no well-known risk factors for IA were present in the two cases with probable IA. An additional reason for the lower prevalence in this study may be that patients admitted on weekends or holidays who died within 48 h would not have been included in our study as we were not able to screen the emergency departments and wards on these days. However, in hospital mortality rate within the first 48 h of admission was very low in our study (only two from 154 screened patients; one before and one after study inclusion). We therefore assume that the number of patients missed was low. Furthermore, the single patient who died shortly after admission and prior to study inclusion due to acute bleeding of esophageal varices had no evidence for IA on autopsy.
Besides patients with alcoholic hepatitis, IA cases were primarily reported in patients with end-stage cirrhosis (Child-Pugh stage C). 7, 8, 10 Even though 46% patients of our study population were in Child-Pugh C stadium of liver cirrhosis, we could not observe a single case of IA in these patients. Both IA cases from our study occurred in ChildPugh A liver cirrhosis patients. This may be of particular interest, as up to date only cirrhotic patients admitted to ICUs with far advanced cirrhosis have been considered at risk for IA. The low rate of IA reported in cirrhotic patients with Child-Pugh A or B liver cirrhosis may be explained by low awareness of physicians for IA in early stage liver cirrhosis and limited performance of screening tools for IA in non-neutropenic patients. 7 As angioinvasive growth of Aspergillus spp. is more commonly found in neutropenic patients compared to non-neutropenic patients, serum GM detection may be more reliable in case of underlying neutropenia and tend to yield false negative results in case of lack of neutropenia. 26, 27 This is also supported by our data, as serum GM results remained negative in one out of two IA cases. Bronchoscopy was performed rapidly in this patient and BALF GM testing yielded a highly positive GM result (3.44 ODI) underlining the importance of timely BALF diagnostics in case of suspicion of pulmonary aspergillosis as also published in the 2016 guidelines for diagnosis and management of aspergillosis by the Infectious Disease Society of America. 28 . In contrast, BALF GM testing resulted negative in patient 2, in whom bronchoscopy was delayed until 9 days after initiation of antifungal treatment. The negative BALF GM result in this setting can be explained by the reduced sensitivity of BALF GM testing in the presence of mould-active antifungal treatment (52% vs. 71% in those without antifungals according to a recent study 29 ).
GM screening in our cohort was highly specific but limited by a low PPV. A positive serum GM test was only associated with a 17% probability of having probable IA. The PPV would have increased to 50%, however, if only patients with clinical suspicion for IA would have been tested for GM while sensitivity, specificity, and NPV remained the same. Similar data have previously been published by Duarte and colleagues for patients with hematological malignancies receiving mould-active prophylaxis. 30 They reported a PPV for serum GM screening of 12% only when screening hematological patients under antifungal prophylaxes regardless of symptoms, but 89.6% when only testing symptomatic patients with clinical suspicion of IA. 30 These comparable trends in very different patient populations can be explained by a low pretest probability of IA in both populations. By increasing the pretest probability (e.g., screening only symptomatic patients which increased the pretest probability of IA from 1.3% to 15.4% in our study) the chance of getting a true positive test result increases substantially. Based on the low prevalence of IA in our study cohort, GM testing only in case of clinical suspicion may therefore be preferable for similar patient populations when compared to universal GM screening. None of the patients with respiratory symptoms tested positive for serum GM. This may be explained by the low number of IA cases and the fact that only one of two patients with IA had respiratory symptoms (hemoptysis) but a negative serum GM result. Considering the imperfect sensitivity of serum GM in non-neutropenic patients, 27 clinical suspicion of IA should therefore definitively trigger further investigations to either diagnose or rule out presence of IA. Compared to neutropenic patients, "typical" respiratory symptoms such as cough and chest pain and even fever are less frequently observed in non-neutropenic patients during early stages of IA 18, 31 and also absent in one of the patients with probable IA described here. One may argue that potential confounding factors, like IV antibiotics, immunoglobulins, and so forth caused false positive GM levels in the two patients with IA, and thus these patients were therefore misclassified as having IA. As we could not observe factors that are known to potentially cause false positive GM levels in these two patients and both patients improved clinically after voriconazole initiation, we are confident to state that these two patients were suffering from IA.
Both of our patients with probable IA received voriconazole, the first line treatment for IA. 32, 33 Besides a temporary and reversible AST elevation in both patients (118-176 U/l in patient 1 and 102-314 in patient 2 voriconazole therapy was not associated with deterioration of liver function or increasing liver function tests. Nevertheless, riskbenefit assessment of voriconazole therapy in patients with underlying liver disease is very important as voriconazole is a known hepatotoxic antifungal agent and newer agents with less hepatotoxicity have become available. Moreover, voriconazole is metabolized by cytochrome P-450 isoenzymes leading to various relevant drug-drug interactions. 34 In case of oral voriconazole treatment, the rate of acute liver injury in patients with underlying chronic liver diseases may be relatively low. 35 The crude mortality among patients with end stage liver diseases and IA was 53.5% in a review by Jeurissen and colleagues 8 and reached 100% in the study by Gustot et al. 22 In contrast, both patients with IA in our study survived. These differences in mortality rates may be explained by less advanced stages of liver cirrhosis observed in this study, as well as earlier diagnosis of IA (post mortem IA diagnosis was frequent in the two prior reports), a very low proportion of patients receiving high-dose glucocorticoids in this study and the well-tolerated therapy with voriconazole. Our study has several limitations. First, we used modified EORTC/MSG criteria for defining IA that include antigen testing (GM) as part of their mycological criteria. Consequently, performance of GM testing may be overestimated in this study in terms of an incorporation bias. Second, serum GM performance is an imperfect screening tool for IA in non-neutropenic patients, and prevalence of IA was therefore most likely underestimated in this study. Also, high serum bilirubin levels may influence serum GM results, as recently published. 39 Alternative screening approaches, using chest CT scans or bronchoscopy and BALF GM testing, however, would raise some serious ethical issues and expose the patients to an unacceptably high risk of complications. We therefore decided to use these modified EORTC/MSG criteria as diseases definition as it was done in previous studies. 4, 22 Third, this study was conducted as a single center study at a reference center for liver cirrhosis and liver transplantation. Data may therefore not be generalized and need to be confirmed in larger case control studies.
In conclusion, we found a prevalence of 1.3% of IA in patients with underlying liver cirrhosis. Targeted GM testing in case of clinical suspicion of IA may therefore be associated with markedly higher PPVs when compared to universal GM screening in patients with liver cirrhosis.
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